The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

California Healthline: Silence On E. Coli Outbreak Highlights How Trump Team’s Changes Undermine Food Safety Food ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

GLP-1 drugs like Ozempic are revolutionizing diabetes care. But they’re also making users less likely to drink alcohol. That ...